Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Lankheet, Nienke A. G., Desar, Ingrid M. E., Mulder, Sasja F., Burger, David M., Kweekel, Dinemarie M., van Herpen, Carla M. L., van der Graaf, Winette T. A., van Erp, Nielka P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Pharmacokinetics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595974/
https://ncbi.nlm.nih.gov/pubmed/28500677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13327
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller